I like this for a more in depth explanation of the results.
movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.29633
" This finding, together with the observation that clinical progression, correlates with imaging progression, suggests that the present lmaging biomarker anticipates anticipates clinical progression, and therefore qualifies as at least a medium grade surrogate marker of disease progression"
That ATH want to add the atrophy measurement as a primary trial endpoint, suggests they have already seen it in the open label study. If atrophy does anticipate clinical progression, you may be right Scott. exciting times ahead for holders and patients.
- Forums
- ASX - By Stock
- ATH
- Short activity
Short activity, page-9
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
HCH
Hot Chili sets up water company as drought racks Chile–but must also build communities a desal plant
Add ATH (ASX) to my watchlist
|
|||||
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $4.125K | 824.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
58 | 64293651 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 29230739 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
58 | 64293651 | 0.004 |
48 | 46148652 | 0.003 |
17 | 39764402 | 0.002 |
13 | 92470101 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 29230739 | 21 |
0.006 | 34263249 | 13 |
0.007 | 17470649 | 16 |
0.008 | 14399594 | 14 |
0.009 | 6000000 | 5 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |